NCT04565171

Pharmacokinetics of Yimitasvir Phosphate Capsule in Subjects With Normal Renal Function and ESRD

A Single-center, Non-randomized, Open-Label, Single-Dose Study to Evaluate the Pharmacokinetics of Yimitasvir Phosphate Capsule in Subjects With Normal Renal Function and End-stage Renal Disease Without Hemodialysis

• Status: Completed
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 16 (actual)
• Sponsor: Sunshine Lake Pharma Co., Ltd. · Industry
• Sex: All
• Age: 18 Years – 70 Years
• Healthy volunteers: Accepted

Summary

This study is to evaluate the single-dose pharmacokinetics (PK) and safety of Yimitasvir phosphate capsule in participants with End-stage renal disease without hemodialysis using matched healthy participants as a control group.

Conditions

• Renal Impairment

Interventions

Type	Name	Description
DRUG	Yimitasvir Phosphate Capsule	DAG181 100 mg (100 mg Capsule) administered orally

Timeline

• Start date: 2021-04-15
• Primary completion: 2022-05-07
• Completion: 2022-05-07
• First posted: 2020-09-25
• Last updated: 2022-10-27

Locations

1 site across 1 country: China